If everything fell into place perhaps, more likely 2Q. Assuming positive data that is.
Maybe if they are lucky enough & schedule it correctly they could walk into the FDA review meeting with positive (?) 306 data in hand, which could speed things up a bit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.